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Surgical intervention is the mainstay treatment for soft tissue sarcomas (STSs). The
significance of adjuvant and neoadjuvant therapies, such as chemotherapy, radia-
tion, and isolated limb perfusion, remains under controversial discussion. The goal
of this review is to discuss the effects of the aforementioned treatment modalities
and their timing of application in plastic surgery techniques. Furthermore, options of
reconstruction in cases of complications caused by adjuvant and neoadjuvant ther-
apies are discussed. When compared with adjuvant radiation, neoadjuvant treatment
can reduce negative side effects such as fibrosis and edema because radioderma
can be removed during the subsequent surgical procedure. Furthermore, there have
not been any reports of negative effects of neoadjuvant radiation on microsurgical
procedures. However, the dose of neoadjuvant radiation correlates with increased
risks of impaired wound healing postoperatively. Thus, a patient-specific approach to
decide whether radiation should be performed adjuvant or neoadjuvant is necessary.
Preoperative irradiation should be considered in cases where functional structures
are exposed after tumor resection, in order to ensure the best possible functionality.
Adjuvant radiation should be considered in all other cases because of its known
superior wound healing. As for chemotherapy, no negative influence of its use adju-
vant or neoadjuvant to reconstructive procedures, such as local or free flaps, has
been reported. Lastly, small sample size studies have not shown increased risks of
microsurgical failure or wound complications after isolated limb perfusion. The find-
ings of this review suggest that the chronological order of the discussed therapeutic
approaches is not a decisive factor in the surgical outcome of reconstructive procedures
for STS.
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BACKGROUND
Arising from the mesenchymal connective tissues, the heteroge-
neous group of soft tissue sarcomas (STS) occurs subcutaneous
or deep in the extremities in 60% of cases (1). Surgical resection
is the mainstay treatment of STS, and margin status is the most
important prognostic factor. Margin status is usually documented
according to the classification defined byEnneking et al. as intrale-
sional (biopsy), marginal (resection through the pseudocapsule
and pretumoral reactive tissue), wide (resection including sur-
rounding “normal” tissue outside the reactive zone, but within
the involved anatomical compartment), or radical (compartment
resection) (2). Historically, amputation or compartment resection
is most often chosen in order to ensure complete tumor removal.
Modern limb salvage techniques combined with neoadjuvant or
adjuvant radiotherapy are now the standard treatment options
for extremity STS. Sparing adjacent critical structures is safe and
contributes to improved functional outcomes (3). Nevertheless,
due to the heterogeneity of histological STS subtypes and of
responses to chemotherapy, radiation, and isolated limb perfu-
sion, the significance of adjuvant and neoadjuvant options in
multimodal therapeutic approaches were a controversial topic of
discussion in the past (1). In 1982, Rosenberg et al. showed that
there was no difference in local tumor control and disease-free
survival between amputation and limb-saving surgery followed by
radiation (4). In addition, further studies showed similar results
for marginal, wide or radical resection incorporated into pre- and
postoperative radiation (5, 6).
Sarcoma resection should be performed in specialized cancer
centers. Preoperative diagnostic measures, such as magnetic res-
onance imaging (MRI), are indispensable to define the expected
surgical margins. Tumor resection frequently affects exposed
functional structures, such as bones, joints, tendons, blood vessels,
or nerves in addition to soft tissue defects, introducing the need
for reconstructive procedures that include local or free flaps and
motor replacement surgery. Therefore, plastic surgery methods
have to be included in the multimodal approach, and the pref-
erence is shifted from conventional simple techniques of wound
closure toward microsurgical procedures that enable the transfer
of uninvolved tissues to the affected region. Furthermore, recon-
structive surgery can help treat complications caused by adjuvant
and neoadjuvant therapies. The timepoint at which additional
treatments are introduced directly affects the planning for and the
outcomes of tumor resection and reconstructive plastic surgery
techniques.
The goal of this review is to show the influence of the timing
of introduction of additional treatments for STS, such as radia-
tion, chemotherapy, and isolated limb perfusion, on the surgical
techniques used for reconstruction following tumor resection.
RADIOTHERAPY
Despite years of experience, the role of radiotherapy in the
treatment of extremities STS was not fully established in the
past (1). It has been demonstrated that neoadjuvant irradiation
provides no significant benefit in local control of the tumors
and/or development of distant metastasis when compared with
adjuvant treatment (6, 7). Moreover, the influence of neoadju-
vant irradiation on subsequent plastic surgery techniques remains
controversially discussed. As radiation theoretically sterilizes the
reactive zone surrounding the tumor, neoadjuvant radiation may
allowmarginal excision to be safely performed around vital struc-
tures without compromising local control rates (6). Neoadjuvant
irradiation enables a smaller radiation field size when compared
with adjuvant irradiation (8).
After neoadjuvant radiotherapy, complete removal of sur-
rounding radioderma prior to soft tissue coverage via plastic
surgery can be performed. As a result, late radiation effects,
such as fibrosis, caused by increased collagen synthesis as a side
effect of external radiotherapy and edema can be reduced. This
procedure is of major interest in cases of exposed functional
structures, such as tendons or joints where fibrosis and edema
can compromise functional restrictions. Furthermore, preopera-
tive treatment prevents the delay between irradiation and surgi-
cal resection that is caused by a possible compromised wound
healing when radiotherapy is performed adjuvant. Several stud-
ies showed that neoadjuvant radiation has no negative effect
on microsurgical procedures, including free flaps (9–11). For
afferent vessels located in postradiogenic altered tissue, there
was no significant increase of complications. Even though pre-
operative radiotherapy typically involves a lower dose of radia-
tion when compared with postoperative radiotherapy, the risk of
impaired postoperative wound healing rises in direct correlation
with the neoadjuvant radiation dose (12). O’Sullivan reported
that 35% of patients receiving preoperative radiotherapy (50Gy
in 25 fractions) and 17% of patients receiving postoperative
radiotherapy (66Gy in 33 fractions) developed wound compli-
cations irrespective of the surgical procedure (primary closure
or plastic surgery) (7, 12). Other authors reported that 21–37%
of the patients who received neoadjuvant radiation developed
serious local wound complications including infection, tissue
necrosis, seroma, and dehiscence, particularly at the proximal
lower extremity (36 vs. 15–27% for other locations) (6, 13).
Interestingly, for the upper extremity, much less wound healing
problems were described compared to the lower extremity after
neoadjuvant radiation therapy (7). Thus, a different regimen of
therapy chronology can be considered for the upper extremity.
Nevertheless, additional surgical procedures aimed to control
wound morbidity were necessary in 16–23% of the cases (13, 14).
On the other hand, rates of fibrosis were increased in patients
who received adjuvant treatment. Radiation doses of 50–60Gy
within 6weeks after surgery can reduce local recurrence, but fibro-
sis and postradiogenic altered skin can provoke chronic ulcera-
tion in an otherwise adequately healed transplant (15). Resulting
unstable scars and fibrotic tissue may cause inferior functional
outcomes (16).
High-dose-rate brachytherapy provides a constant dose to
the target and very low doses to nearby radiosensitive tissues.
Sharma et al. reported that perioperative high-dose-rate inter-
stitial brachytherapy in combination with external beam radia-
tion therapy provides excellent local control and survival rates
(follow-up 46months) with acceptable acute and late toxicities
(17). Delayed wound healing was observed in 5.7% of cases,
whereas chronic skin lesions and fibrosis were observed in 9.6%
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FIGURE 1 | Recurrence of a myofibroblastic sarcoma (TNM
classification: pT2b pNX M0, G1) of the left lower leg 13 years after
tumor resection and free latissimus dorsi transfer. Status post
neoadjuvant isolated limb perfusion.
FIGURE 2 | Preoperative planning of tumor resection (R0).
FIGURE 3 | Elevation of an anteriomedial thight (AMT) flap and
dissection of the pedicle.
(17). Nevertheless, other studies demonstrated an increased rate
of impaired wound healing after brachytherapy combined with
neoadjuvant radiation when compared with external radiation,
irrespective of the reconstructive approach (18). The overall
higher radiation dose might be an explanation for these findings.
No negative influence to microsurgical reconstruction has been
described (19). However, it is important to note that the source
FIGURE 4 | Postoperative result after complete wound healing.
of radiation should be placed at the maximal distance possible to
the anastomosis because local radiation treatment decreases vessel
wall strength (20).
CHEMOTHERAPY
Just as in the case of radiotherapy discussed above, the role of
adjuvant or neoadjuvant chemotherapy in the treatment of STS
is controversial due to the low response rate and toxic adverse
effects. Marginal positive effect to the disease-free surviving was
reported in several meta-analyses in the past (21). Nevertheless,
for first line therapy including Doxorubicin and Ifosfamide, a
response rate of up to 30% is described while no benefit in relapse-
free survival or overall survival could be shown (22, 23). Based on
these findings, adjuvant chemotherapy should be limited to high-
risk patients with extensive, highly malignant STS in the setting of
controlled clinical studies (23).
There have been no reports to the authors’ knowledge of neg-
ative influence of chemotherapy on reconstructive procedures
involving local or free flaps. However, it is noted that adjuvant
treatment should not start before completion of wound healing
because there is a known increased risk of wound complications
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associated with chemotherapy (6). Sanniec et al. showed wound
complications in 49% of cases of combined sarcoma resection and
chemotherapy (24).
Extravasation of cytostatic drugs during peripheral intravenous
administration is a potentially severe complication of chemother-
apy. The frequency of extravasation is considered to be between
0.6 and 6% (25). The extent of local tissue injury depends on
the chemical structure of the applied substance, which is classi-
fied as vesicant, irritant, and non-irritant. According to current
references, treatment of chemotherapy drug extravasation should
be managed in specialized centers (26). Surgical interventions
are indicated in cases of extensive necrotic areas or failure of
conservative measures. After surgical debridement, reconstruc-
tive procedures, such as split-thickness skin grafts or randomized
fasciocutaneous flaps, prevent prolonged secondary wound heal-
ing. Thus, plastic surgical treatment enables early and complete
remission of the lesions and reduces the delay in administration
of further chemotherapy (27).
ISOLATED LIMB PERFUSION
For the treatment of locally advanced STS in the extremities,
isolated limb perfusion with TNF-alpha andmelphalan (TM-ILP)
has proven to be a effective treatment modality with limb salvage
rates of ~87% and response rates of 71% (28, 29). Tumor size
reduction induced by TM-ILP can render non-resectable tumors
to resectable.
Unfortunately, there is limited available data for reconstruc-
tive procedures following isolated limb perfusion. Even when
local complications, such as impaired wound healing and lym-
phocutaneous fistulas are described, small sample size studies
demonstrated no increased risk of microsurgical failure or wound
complications (30). Functional results after limb-sparing surgery
were shown to be satisfactory (31).
CONCLUSION
Interdisciplinary treatment involving pathologists, radiologists,
surgeons, radiation therapists, and medical oncologists is manda-
tory in cases of STS. Therapy planning and performance should
be carried out at referral centers for sarcomas that can provide the
necessary multidisciplinary environment. Irradiation represents a
mainstay in treatment. The significance of chemotherapy and iso-
lated limbperfusion on the outcomes of reconstructive procedures
following STS resection is yet to be elucidated. The chronology of
radiation, chemotherapy, limb perfusion, and surgical resection
appears to have no influence on the success of reconstructive
procedures, such as microsurgical tissue transfers (Figures 1–4).
Most surgeons prefer postoperative radiation because it may
afford decreased risks of wound complications. In cases of neoad-
juvant radiation, free flapsmay be performed for soft-tissue recon-
struction. Several studies showed superior functional outcomes
with preoperative, rather than postoperative radiotherapy. Pre-
and postoperative irradiation mainly affects plastic surgery pro-
cedures in terms of impaired wound healing and fibrosis. Further
studies will be necessary to elucidate the effects of chemotherapy
and isolated limb perfusion on the outcomes of reconstructive
procedures following resection of STSs.
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